KROS logo

Keros Therapeutics Inc. (KROS)

$11.31

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on KROS

Market cap

$221951670

EPS

-2.34

P/E ratio

--

Price to sales

15.78

Dividend yield

--

Beta

1.132047

Price on KROS

Previous close

$10.03

Today's open

$10.02

Day's range

$10.02 - $11.80

52 week range

$8.98 - $22.55

Profile about KROS

CEO

Jasbir Seehra

Employees

92

Headquarters

Lexington, MA

Exchange

NASDAQ Global Market

Shares outstanding

19624374

Issue type

Common Stock

KROS industries and sectors

Healthcare

Biotechnology & Life Sciences

News on KROS

Keros Therapeutics Announces Additional $5 Million Share Repurchase Authorization

LEXINGTON, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that its Board of Directors has approved a new $5 million share repurchase program of the Company's common stock following receipt of a $20 million development milestone payment under the license agreement of elritercept with Takeda Pharmaceuticals U.S.A., Inc., following the dosing of the first patient in the ELRiSE MF clinical trial. This approval grants Keros' management the authority to repurchase outstanding shares of the Company's common stock, from time to time, in the open market and/or by such other means in accordance with applicable state and federal securities laws.

news source

GlobeNewsWire • Nov 16, 2026

news preview

New Strong Buy Stocks for November 12th

PANL, CBRL, KROS, NEPH and LRN have been added to the Zacks Rank #1 (Strong Buy) List on November 12, 2026.

news source

Zacks Investment Research • Nov 12, 2026

news preview

Down 21% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround

Keros Therapeutics (KROS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

news source

Zacks Investment Research • Nov 10, 2026

news preview

Keros Therapeutics, Inc. (KROS) Q3 Earnings and Revenues Surpass Estimates

Keros Therapeutics, Inc. (KROS) came out with quarterly earnings of $0.7 per share, beating the Zacks Consensus Estimate of a loss of $0.96 per share. This compares to a loss of $0.18 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage

Keros Therapeutics NASDAQ: KROS is repositioning its pipeline around rinvatercept, a skeletal-muscle regeneration candidate being developed for neuromuscular diseases, while its partnered program eleriscept advances through late-stage development under Takeda, Chief Executive Officer Jasbir Seehra said during a fireside chat hosted by Chardan.

news source

MarketBeat • Oct 22, 2026

news preview

Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda

LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MF clinical trial. ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis (“MF”) and anemia on concurrent ruxolitinib therapy.

news source

GlobeNewsWire • Sep 29, 2026

news preview

KROS Begins Dosing in Phase II Study With Rinvatercept in DMD

Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.

news source

Zacks Investment Research • Sep 29, 2026

news preview

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the first patient was dosed in the Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy (“DMD”).

news source

GlobeNewsWire • Sep 28, 2026

news preview

Keros Therapeutics Announces $5 Million Share Repurchase Authorization

LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that its Board of Directors has approved a $5 million share repurchase program of the Company's common stock following receipt of a $20 million development milestone payment under the license agreement of elritercept with Takeda Pharmaceuticals U.S.A., Inc., following the dosing of the first patient in the ELRiSE MDS clinical trial. This approval grants Keros' management the authority to repurchase outstanding shares of the Company's common stock, from time to time, in the open market and/or by such other means in accordance with applicable state and federal securities laws.

news source

GlobeNewsWire • Sep 8, 2026

news preview

Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?

Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?

news source

Zacks Investment Research • Sep 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Keros Therapeutics Inc.

Open an M1 investment account to buy and sell Keros Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in KROS on M1